Analyzing...
Loading company...
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 24,832 full-time employees. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹33,700 Cr revenue.
COGS 36.3%, employees 17.8%.
“reporting a 4.”
“next two years, we will absolutely get back to, to the growth and to the margins.”
“very comfortable with the 15% plus.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.1%▲ | 10.3% |
| ROCE | 13.9%▲ | 13.7% |
| Net Margin | 12.0%▲ | 7.6% |
| EBITDA Margin | 22.3%▲ | 15.4% |
| Debt To Equity | 0.17x▲ | 0.15x |
| Rev Growth 3yr | 10.9%▲ | 10.0% |
| EPS Growth 3yr | -2.4%▼ | 16.0% |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33,228 Cr +1.8% | ₹32,644 Cr +16.5% | ₹28,011 Cr +13.5% | ₹24,670 Cr +14.5% | ₹21,545 Cr +13.1% | ₹19,048 Cr +8.7% | ₹17,517 Cr +13.4% | ₹15,448 Cr |
| Other Income | ₹1,423 Cr +29.7% | ₹1,097 Cr +22.7% | ₹894 Cr -15.3% | ₹1,056 Cr +117.9% | ₹484 Cr +66.2% | ₹291 Cr -53.0% | ₹621 Cr +83.9% | ₹338 Cr |
| Total Income | ₹34,651 Cr +2.7% | ₹33,741 Cr +16.7% | ₹28,905 Cr +12.4% | ₹25,725 Cr +16.8% | ₹22,030 Cr +13.9% | ₹19,339 Cr +6.6% | ₹18,138 Cr +14.9% | ₹15,786 Cr |
| COGS | ₹12,817 Cr +28.4% | ₹9,980 Cr +21.6% | ₹8,209 Cr +7.2% | ₹7,658 Cr +2.9% | ₹7,442 Cr +22.4% | ₹6,079 Cr +9.4% | ₹5,554 Cr +23.6% | ₹4,495 Cr |
| ₹30,624 Cr +17.4% | ₹26,083 Cr +20.1% | ₹21,719 Cr +10.2% | ₹19,714 Cr +3.5% | ₹19,039 Cr +15.4% | ₹16,503 Cr +1.2% | ₹16,308 Cr +20.9% | ₹13,494 Cr | |
| Profit Before Tax | ₹4,027 Cr -47.4% | ₹7,658 Cr +6.6% | ₹7,186 Cr +19.5% | ₹6,012 Cr +101.0% | ₹2,991 Cr +5.5% | ₹2,836 Cr +55.0% | ₹1,830 Cr -20.2% | ₹2,292 Cr |
| ₹858 Cr -56.1% | ₹1,954 Cr +20.4% | ₹1,623 Cr +5.3% | ₹1,541 Cr +75.4% | ₹879 Cr -5.7% | ₹932 Cr ↑ Recovery | (₹140 Cr) ↓ Decline | ₹386 Cr | |
| Net Profit | ₹3,183 Cr -44.4% | ₹5,725 Cr +2.6% | ₹5,578 Cr +23.8% | ₹4,507 Cr +106.5% | ₹2,183 Cr +11.8% | ₹1,952 Cr -3.7% | ₹2,026 Cr +3.9% | ₹1,950 Cr |
| Profit (Owners) | ₹3,222 Cr -43.0% | ₹5,655 Cr +1.4% | ₹5,578 Cr +23.8% | ₹4,507 Cr +106.5% | ₹2,183 Cr +11.8% | ₹1,952 Cr -3.7% | ₹2,026 Cr +3.9% | ₹1,950 Cr |
| Minority Interest | (₹39 Cr) ↓ Decline | ₹70 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹690 Cr +236.6% | ₹205 Cr ↑ Recovery | (₹66 Cr) -442.1% | (₹12 Cr) +95.8% | (₹290 Cr) ↓ Decline | ₹540 Cr ↑ Recovery | (₹65 Cr) +40.2% | (₹109 Cr) |
| EPS | ₹38.61 | ₹67.77 | ₹66.87 | ₹54.13 | ₹26.23 | ₹23.47 | ₹24.38 | ₹23.48 |
| Diluted Shares | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr |
| Profit Or Loss Of Associates | ₹14 Cr -35.5% | ₹22 Cr +47.6% | ₹15 Cr -60.3% | ₹37 Cr -47.4% | ₹70 Cr +46.5% | ₹48 Cr -14.4% | ₹56 Cr +28.1% | ₹44 Cr |
Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
The Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddys antibiotic gets Thailand approval six months after US nod. The respons...
Dr. Reddy's Laboratories Limited has informed the Exchange about Transcript
The Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddys antibiotic gets Thailand approval six months after US nod. The respons...
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 23, 2026. Further, the company has submitted the Exchange a copy of Srutinizers ...
Dr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Intimation of Earnings call recording".
Dr. Reddy's Laboratories Limited has informed the Exchange about Investor Presentation
Dr. Reddy's Laboratories Limited has informed the Exchange about allotment of Employee Stock Options
Dr. Reddy's Laboratories Limited has informed the Exchange about change in Management
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Dr. Reddy's Laboratories Limited has informed the Exchange about Conference call Transcript
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 13, 2026, titled "Intimation of Earnings call".